AMPIO PHARMACEUTICALS, INC. AMPE Balance Sheet

Ampio pharmaceuticals, inc. (AMPE)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Dec'10
Assets
Current assets
Cash and cash equivalents
2,415	6,532	8,044	12,782	5,160	7,585	8,672	4,660	7,517	8,209	1,807	4,940	2,256	4,894	7,416	6,451	11,114	15,998	35,384	36,783	43,271	50,320	56,830	65,635	78,225	26,309	32,070	12,456	16,527	17,682	20,265	6,804	8,292	11,362	6,993	8,374	671
Trading security in Aytu BioScience, Inc.
-	-	-	-	-	-	-	1	3	-	20	60	91	122	333	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Equity investment in Aytu BioScience, Inc. (Note 3)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	268	959	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivable from Aytu BioScience, Inc.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	38	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5
Prepaid expenses and other
1,020	1,718	1,836	1,629	593	447	512	316	383	233	422	641	475	240	-	-	-	321	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	722	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	409	638	432	-	1,591	1,344	283	672	383	1,152	495	131	151	414	350	164	142	306	176	43	116	198	60
Prepaid research and development - related party (Note 10)
-	-	-	-	-	-	-	-	-	-	0	0	143	143	143	143	143	143	265	265	265	265	265	265	254	-	-	-	-	-	-	-	-	-	-	-	-
Current assets of discontinued operations (Note 4)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	12,726	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total current assets
3,435	8,250	9,880	14,412	5,753	8,032	9,184	4,978	7,904	8,442	2,250	5,642	2,967	5,402	8,303	7,502	11,691	29,228	37,241	38,393	43,820	51,259	58,201	67,053	78,975	26,441	32,221	12,871	16,877	17,847	20,408	7,110	8,468	11,405	7,110	8,573	737
Fixed assets, net
4,453	4,748	5,036	5,355	5,677	5,998	6,355	6,658	6,725	6,837	7,102	7,390	7,693	7,980	8,271	8,576	8,882	9,187	9,418	9,628	9,819	9,945	9,805	8,687	4,317	1,298	293	315	327	59	63	67	71	76	80	38	-
In-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,500	7,500	7,500	7,500	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Developed technology, customer contracts and trade names, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,530	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
ProstaScint asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
In-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,500	7,500	7,500	7,500	7,500	7,500	7,500	7,500	7,500	7,500	7,500	7,500	7,500	7,500	-
Patents, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	611	628	646	664	681	699	717	734	752	770	789	420	431	443	454	465	477	488	-
Long-term portion of prepaid research and development - related party (Note 10)
-	-	-	-	-	-	-	-	-	-	0	0	143	179	215	251	287	323	664	730	797	863	930	996	1,074	-	-	-	-	-	-	-	-	-	-	-	-
Deposits
-	-	-	33	33	-	33	33	33	33	33	33	33	33	33	33	33	33	38	38	35	35	33	43	43	43	20	20	20	20	35	35	35	35	37	37	-
Right-of-use asset
959	1,003	1,045	1,087	1,127	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets of discontinued operations, net (Note 4)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	11,645	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total noncurrent assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19,837	19,526	18,799	19,009	18,951	17,927	13,652	9,577	8,566	8,605	8,636	7,999	8,030	8,045	8,061	8,077	8,094	8,063	-
Total assets
8,847	14,001	15,962	20,888	12,592	14,030	15,573	11,671	14,663	15,314	9,387	13,066	10,839	13,595	16,824	16,365	21,854	50,418	57,079	57,920	62,620	70,268	77,152	84,981	92,628	36,018	40,787	21,477	25,513	25,847	28,438	15,156	16,530	19,482	15,205	16,637	737
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable and accrued expenses
4,214	4,025	2,129	1,879	1,278	1,324	1,534	2,175	2,492	2,785	1,027	1,827	765	709	-	-	-	1,804	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,146	1,368	2,210	-	2,310	2,466	1,521	3,299	2,844	3,637	4,422	1,900	1,166	1,759	1,169	1,201	789	358	406	630	471	568	464
Accrued compensation
-	-	-	197	41	-	130	986	982	1,033	1,184	1,263	1,304	1,365	1,205	1,182	1,040	885	1,440	923	537	235	-	-	-	522	-	-	-	-	-	-	-	-	-	-	-
Lease liability-current portion
265	259	253	247	241	60	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued salaries and other liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	526
Accrued interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19
Accrued liabilities - related party (Note 9)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	150	450	600	-	-	-	-	-	-	-	-	-	-	-	193
Accrued bonuses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	37	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent - current portion
-	-	-	-	-	-	59	59	59	59	59	59	59	59	59	59	59	59	59	59	59	59	56	79	-	-	-	-	-	-	-	-	-	-	-	-	-
Current liabilities of discontinued operations (Note 4)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	2,765	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	85	85	85	85	85	85	50	50	50	50	50	50	50	50	50	50	50	-	-
Senior convertible unsecured related party debentures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	608
Senior unsecured manditorily convertible debentures
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,133
Warrant derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	868	621	502	384	457	687	453	610	1,170	1,809	398
Related party notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	400
Total current liabilities
4,479	4,284	2,382	2,324	1,561	1,384	1,723	3,221	3,534	3,878	2,271	3,149	2,129	2,134	2,412	2,611	3,311	5,515	3,895	3,535	2,204	3,679	3,137	4,289	5,072	2,472	2,085	2,431	1,722	1,635	1,297	1,095	910	1,291	1,691	2,378	4,745
Lease liability-long-term
1,142	1,210	1,276	1,342	1,407	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease liability-long-term, Before ASU 2016-02
-	-	-	-	-	477	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible promissory notes, net of unamortized discount of $253,448 (Note 8)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,825	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	57	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	677	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term deferred rent
-	-	-	-	-	-	492	508	523	537	550	564	577	588	599	610	620	629	649	646	654	661	642	270	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant derivative liability
-	-	-	-	-	-	11,120	11,709	19,461	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long-term deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	404	425	447	468	490	511	318	331	343	356	368	381	393	406	418	431	443	-	-
Warrant derivative liability
1,233	2,064	8,200	6,100	10,100	6,933	-	-	-	45,076	6,763	5,617	3,112	4,238	4,039	-	-	0	102	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities of discontinued operations, net (Note 4)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6,346	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities of discontinued operations, net (Note 9)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total liabilities
6,854	7,558	11,825	9,778	13,060	8,794	13,337	15,439	23,520	49,491	9,586	9,331	5,818	6,961	7,050	3,222	3,932	12,491	10,613	4,608	3,306	4,809	4,270	5,071	5,391	2,803	2,428	2,787	2,091	2,017	1,691	1,501	1,329	1,722	2,135	2,378	4,745
Commitments and contingencies (Note 7)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders’ equity
Preferred Stock, par value $0.0001; 10,000,000 shares authorized; none issued
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-	-	0
Common Stock, par value $0.0001; 300,000,000 shares authorized as of 2020 and 2019; shares issued and outstanding - 160,022,000 as of March 31, 2020 and 158,645,000 as of December 31, 2019
16	16	14	14	11	11	10	8	8	8	6	6	5	5	5	5	5	5	5	5	5	5	5	5	5	4	4	3	3	3	3	3	3	3	2	2	1
Additional paid-in capital
191,789	191,060	187,735	187,489	176,335	176,228	174,753	174,551	174,083	170,803	161,656	161,337	160,015	159,732	159,542	158,960	158,687	170,999	168,916	167,975	169,555	168,108	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Additional paid-in capital
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	165,379	163,041	161,435	96,942	94,553	68,691	67,030	63,687	62,927	47,251	46,302	46,061	37,186	35,822	5,961
Issuances for promotion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3
Advance to stockholder
-	-	-	-	-	-	-	-	-	-	0	0	0	25	50	90	90	90	90	90	90	90	90	90	90	90	90	90	90	90	90	90	90	127	127	150	150
Accumulated deficit
-189,812	-184,633	-183,612	-176,393	-176,814	-171,003	-172,527	-178,329	-182,949	-204,988	-161,862	-157,609	-155,000	-153,078	-149,723	-145,731	-140,679	-133,914	-123,909	-116,543	-109,188	-101,904	-91,992	-82,712	-	-63,779	-	-	-	-	-	-	-	-	-	-	-
Deficit accumulated in the development stage
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	74,021	-	56,438	50,366	43,949	39,770	36,093	33,509	31,013	28,177	23,991	21,415	9,818
Total stockholders’ equity
1,993	6,443	4,137	11,110	-467	5,236	-	-	-	-34,176	-	-	-	-	9,773	13,143	17,922	36,999	44,922	51,346	60,281	66,118	73,301	80,243	87,328	33,077	38,028	18,237	22,994	23,830	26,747	13,654	15,201	17,759	13,070	14,259	-4,008
Non-controlling interests of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	927	1,544	1,965	-967	-659	-418	-333	-91	137	330	452	428	-	-	-	-	-	-	-	-
Total stockholders' equity
-	-	-	-	-	-	2,236	-3,768	-8,856	-	-199	3,734	5,020	6,634	9,773	13,143	17,922	37,926	46,466	53,312	59,314	65,458	72,882	79,910	87,237	33,214	38,358	18,689	23,422	23,830	-	-	-	-	-	-	-
Total liabilities and stockholders’ equity
8,847	14,001	15,962	20,888	12,592	14,030	15,573	11,671	14,663	15,314	9,387	13,066	10,839	13,595	16,824	16,365	21,854	50,418	57,079	57,920	62,620	70,268	77,152	84,981	92,628	36,018	40,787	21,477	25,513	25,847	28,438	15,156	16,530	19,482	15,205	16,637	737